Cargando…

IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases

IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) may have protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in systemic rheumatic conditions and study their properties. Anti-PC and anti-MDA was measured using ELISA in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thiagarajan, Divya, Oparina, Nina, Lundström, Susanna, Zubarev, Roman, Sun, Jitong, Alarcon-Riquelme, Marta, Frostegård, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335044/ https://www.ncbi.nlm.nih.gov/pubmed/32620913 http://dx.doi.org/10.1038/s41598-020-66981-z

Ejemplares similares

Human IgM Antibodies to Malondialdehyde Conjugated With Albumin Are Negatively Associated With Cardiovascular Disease Among 60‐Year‐Olds
por: Thiagarajan, Divya, et al.
Publicado: (2016)

IgM-Antibodies against Phosphorylcholine in Mothers and Normal or Low Birth Weight Term Newborn Infants
por: Frostegård, Anna G., et al.
Publicado: (2014)

Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms
por: Thiagarajan, D., et al.
Publicado: (2020)

Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea
por: Frostegård, Johan, et al.
Publicado: (2007)

Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus
por: Anania, Cristina, et al.
Publicado: (2010)

Antibodies against Phosphorylcholine—Implications for Chronic Inflammatory Diseases
por: Frostegård, Johan
Publicado: (2023)

Antibodies against Native and Oxidized Cardiolipin and Phosphatidylserine and Phosphorylcholine in Atherosclerosis Development
por: Frostegård, Anna G., et al.
Publicado: (2014)

Antibodies against phosphorylcholine in hospitalized versus non-hospitalized obese subjects
por: Jujić, Amra, et al.
Publicado: (2021)

IgM antibodies to oxidized phosphatidylserine as protection markers in cardiovascular disease among 60-year olds
por: Frostegård, Johan, et al.
Publicado: (2017)

Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases
por: de Vries, M. R., et al.
Publicado: (2021)

Antibodies Against Phosphorylcholine Among 60-Year-Olds: Clinical Role and Simulated Interactions
por: Samal, Shailesh Kumar, et al.
Publicado: (2022)

Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality
por: Samal, S. K., et al.
Publicado: (2020)

Antibodies against malondialdehyde among 60-year-olds: prediction of cardiovascular disease
por: Samal, Shailesh Kumar, et al.
Publicado: (2023)

Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes
por: Samal, Shailesh Kumar, et al.
Publicado: (2020)

Immunization with gingipain A hemagglutinin domain of Porphyromonas gingivalis induces IgM antibodies binding to malondialdehyde-acetaldehyde modified low-density lipoprotein
por: Kyrklund, Mikael, et al.
Publicado: (2018)

Recognition of Porphyromonas gingivalis Gingipain Epitopes by Natural IgM Binding to Malondialdehyde Modified Low-Density Lipoprotein
por: Turunen, S. Pauliina, et al.
Publicado: (2012)

Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study
por: Elkan, Ann-Charlotte, et al.
Publicado: (2009)

IgM antibodies against phosphorylcholine measured early after acute ST-elevation myocardial infarction in relation to atherosclerotic disease burden and long-term clinical outcome
por: Knudsen, Eva Cecilie, et al.
Publicado: (2019)

Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events
por: Ajeganova, Sofia, et al.
Publicado: (2021)

Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study
por: Elkan, Ann-Charlotte, et al.
Publicado: (2008)

Kinetics of IgM and IgG antibodies after scrub typhus infection and the clinical implications
por: Varghese, George M., et al.
Publicado: (2018)

Cardiovascular co-morbidity in patients with rheumatic diseases
por: Frostegård, Johan
Publicado: (2011)

SpotLight Proteomics—A IgG-Enrichment Phenotype Profiling Approach with Clinical Implications
por: Lundström, Susanna L., et al.
Publicado: (2019)

Altered Fc galactosylation in IgG(4) is a potential serum marker for chronic lung disease
por: Heyder, Tina, et al.
Publicado: (2018)

Protective Roles of Natural IgM Antibodies
por: Grönwall, Caroline, et al.
Publicado: (2012)

IgG Antibodies to Cyclic Citrullinated Peptides Exhibit Profiles Specific in Terms of IgG Subclasses, Fc-Glycans and a Fab-Peptide Sequence
por: Lundström, Susanna L., et al.
Publicado: (2014)

Low levels of IgM antibodies to oxidized cardiolipin increase and high levels decrease risk of cardiovascular disease among 60-year olds: a prospective study
por: Su, Jun, et al.
Publicado: (2013)

Phosphorylcholine Allows for Evasion of Bactericidal Antibody by Haemophilus influenzae
por: Clark, Sarah E., et al.
Publicado: (2012)

GENETICS OF A NEW IgV(H) (T15 IDIOTYPE) MARKER IN THE MOUSE REGULATING NATURAL ANTIBODY TO PHOSPHORYLCHOLINE
por: Lieberman, R., et al.
Publicado: (1974)

Structure, Function, and Therapeutic Use of IgM Antibodies
por: Keyt, Bruce A., et al.
Publicado: (2020)

MONOCLONAL PRODUCTION OF BOTH IgM AND IgG1 ANTIHAPTEN ANTIBODY
por: Press, Joan L., et al.
Publicado: (1973)

Patterns of IgG and IgM antibody response in COVID-19 patients
por: Liu, Xuemei, et al.
Publicado: (2020)

Detection of IgM and IgG antibodies in patients with coronavirus disease 2019
por: Hou, Hongyan, et al.
Publicado: (2020)

SARS-COV-2 IgG and IgM Antibodies in Cancer Patients
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies
por: Fernandes-Cerqueira, Cátia, et al.
Publicado: (2018)

Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden
por: Ärlestig, Lisbeth, et al.
Publicado: (2011)

IgG, IgM and IgA antibodies against the novel polyprotein in active tuberculosis
por: Feng, Xiaoyan, et al.
Publicado: (2014)

Competition between Serum IgG, IgM, and IgA Anti-Glycan Antibodies
por: Muthana, Saddam M., et al.
Publicado: (2015)

Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis
por: Kokkonen, Heidi, et al.
Publicado: (2011)

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
por: Silajdžić, Edina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8t5vc3d89bdut6pvl7i5g3dtr8